Researchers at CTAD announced the end for two active immunotherapies, along with the curious story of a placebo as a treatment and the start of a new antibody.
Researchers at CTAD reported seeing biomarkers budge in active and passive immunotherapy trials, but measurement techniques and screening protocols still need improvement for early stage trials to succeed.
A CAP symposium opened the CTAD conference, indicating that presymptomatic treatment and “federated” research have become mainstream thinking in Alzheimer’s therapy development. EPAD is pulling together European sites.
At CTAD, former FDA neurology leader Rusty Katz urged Alzheimer’s trialists to stop fussing over disease progression. He recommended going after a large effect, regardless of whether it can garner a label of disease modification. That, he says, may mean combination trials.
Lipoprotein cap on pigment cell exosomes is essential for production of an amyloid scaffold that concentrates melanin.
A new trend in cell biology points to vesicles released from cells as agents that form and spread pathogenic proteins.
The amino terminus toggles between a neatly folded nucleic acid-binding domain and a disorganized configuration that forms inclusions.
Tiny secreted vesicles emerge as important players in communication between brain cells. Are they important in neurodegeneration?
Tiny vesicles called exosomes can rid cells of garbage when they get spewed into extracellular space. However, scientists are beginning to realize that these exosomes carry more than just trash. They serve as a means of communication, ferrying messages among cells. Exosomes are not always harbingers of good news. In the brain, they may spread pathogenic proteins, and they pack signals that can overpower immune cells. At the Society for Neuroscience Annual meeting, held November 15 to 19 in Washington, D.C., scientists discussed new insights into exosomes. A picture is emerging of how these vesicles make themselves useful, and sometimes troublesome, in the nervous system. [Image © Kaidor]
Held in a historic skyscraper built in 1932 for a Philadelphia bank, the seventh conference on Clinical Trials on Alzheimer’s Disease drew 715 scientists to this city between November 20 and 22. CTAD featured a sprinkling of new trial results and enthusiasm about treating agitation in AD, but most of the activity reflected a field trying to rebuild itself from the ground up. Trialists swapped notes on implementing new diagnostic criteria in therapy trials, enriching trial populations, and exploring home-based assessments and other tools to support prevention trials. Secondary prevention sounded positively mainstream and has become the stuff of large-scale collaborations. Rusty Katz, formerly of the FDA, implored trialists to stop obsessing over disease modification and to aggressively go after big therapeutic effects instead. Those, Katz said, may require a commitment to co-develop combinations of investigational drugs. Read Madolyn Rogers and Gabrielle Strobel’s series in the coming days.
Don’t miss out on the 12th International Conference on Alzheimer’s and Parkinson’s Diseases and related disorders, to be held March 18 – 22, 2015, in Nice, France. Early registration closes Wednesday, December 17. For further details please visit the conference website.
The Keystone Symposia on Molecular and Cellular Biology will host a meeting on Neuroepigenetics February 22-26, 2015, at the Eldorado Hotel and Spa in Santa Fe, New Mexico. Act now to shave $150 off your registration fee. The early registration deadline is Thursday, December 18. For more information and to register please visit the conference website, http://www.keystonesymposia.org/15B5.
- Martin Citron on Pharmacological Inhibition of Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 Can Impair Synaptic Plasticity and Specific Cognitive Functions
- Stefan Lichtenthaler on Pharmacological Inhibition of Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 Can Impair Synaptic Plasticity and Specific Cognitive Functions
- Michael van Es on Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes.
- Marc Aurel Busche on Dendritic structural degeneration is functionally linked to cellular hyperexcitability in a mouse model of Alzheimer's disease.
- Igor Timofeev on Dendritic structural degeneration is functionally linked to cellular hyperexcitability in a mouse model of Alzheimer's disease.
- Jeffrey Cummings, Constantine Lyketsos, Pierre Tariot, Anton Porsteinsson and Elaine R Peskind on A New Drug to Calm Agitation, Uncontrollable Laughing and Crying, in Alzheimer’s?
- Benjamin Wolozin on Angiotensin-Converting Enzyme Inhibitors and Amyotrophic Lateral Sclerosis Risk: A Total Population-Based Case-Control Study.